Repair of acute respiratory distress syndrome in COVID-19 by stromal cells (REALIST-COVID Trial): a multicenter, randomized, controlled clinical trial
EA Gorman, J Rynne, HJ Gardiner… - American Journal of …, 2023 - atsjournals.org
Rationale: Mesenchymal stromal cells (MSCs) may modulate inflammation, promoting repair
in coronavirus disease (COVID-19)–related acute respiratory distress syndrome (ARDS) …
in coronavirus disease (COVID-19)–related acute respiratory distress syndrome (ARDS) …
[HTML][HTML] Repair of Acute Respiratory Distress Syndrome by Stromal Cell Administration in COVID-19 (REALIST-COVID-19): A structured summary of a study protocol …
E Gorman, M Shankar-Hari, P Hopkins, WS Tunnicliffe… - Trials, 2020 - Springer
Objectives The primary objective of the study is to assess the safety of a single intravenous
infusion of Mesenchymal Stromal Cells (MSCs) in patients with Acute Respiratory Distress …
infusion of Mesenchymal Stromal Cells (MSCs) in patients with Acute Respiratory Distress …
[HTML][HTML] Repair of acute respiratory distress syndrome by stromal cell administration (REALIST): a structured study protocol for an open-label dose-escalation phase 1 …
E Gorman, M Shankar-Hari, P Hopkins, WS Tunnicliffe… - Trials, 2022 - Springer
Abstract Background Mesenchymal stromal cells (MSCs) may be of benefit in ARDS due to
immunomodulatory and reparative properties. This trial investigates a novel CD362 …
immunomodulatory and reparative properties. This trial investigates a novel CD362 …
[HTML][HTML] Mesenchymal stromal cell therapy for COVID-19-induced ARDS patients: a successful phase 1, control-placebo group, clinical trial
N Kaffash Farkhad, A Sedaghat, H Reihani… - Stem Cell Research & …, 2022 - Springer
Background Acute respiratory distress syndrome (ARDS) is the devastating complication of
the new COVID-19 pandemic, directly correlated with releasing large amounts of …
the new COVID-19 pandemic, directly correlated with releasing large amounts of …
Cell-based therapy to reduce mortality from COVID-19: Systematic review and meta-analysis of human studies on acute respiratory distress syndrome
Severe cases of COVID-19 infection, often leading to death, have been associated with
variants of acute respiratory distress syndrome (ARDS). Cell therapy with mesenchymal …
variants of acute respiratory distress syndrome (ARDS). Cell therapy with mesenchymal …
Mesenchymal stromal cell therapy for COVID-19 acute respiratory distress syndrome: a double-blind randomised controlled trial
ME Martínez-Muñoz, C Payares-Herrera… - Bone Marrow …, 2024 - nature.com
Mesenchymal stromal cells (MSC) have immunomodulatory and tissue-regenerative
properties and have shown promising results in acute respiratory distress syndrome (ARDS) …
properties and have shown promising results in acute respiratory distress syndrome (ARDS) …
Feasibility study of cord tissue derived mesenchymal stromal cells in COVID-19-related acute respiratory distress syndrome
Background Treatment options for patients with COVID-19-related acute respiratory distress
syndrome (ARDS) are desperately needed. Allogeneic human umbilical cord derived …
syndrome (ARDS) are desperately needed. Allogeneic human umbilical cord derived …
[HTML][HTML] Bone marrow-derived mesenchymal stromal cell therapy in severe COVID-19: preliminary results of a phase I/II clinical trial
C Grégoire, N Layios, B Lambermont… - Frontiers in …, 2022 - frontiersin.org
Background Treatment of acute respiratory distress syndrome (ARDS) associated with
COronaVIrus Disease-2019 (COVID-19) currently relies on dexamethasone and supportive …
COronaVIrus Disease-2019 (COVID-19) currently relies on dexamethasone and supportive …
[HTML][HTML] Human mesenchymal stromal cells are resistant to SARS-CoV-2 infection under steady-state, inflammatory conditions and in the presence of SARS-CoV-2 …
Previous studies reported on the safety and applicability of mesenchymal stem/stromal cells
(MSCs) to ameliorate pulmonary inflammation in acute respiratory distress syndrome …
(MSCs) to ameliorate pulmonary inflammation in acute respiratory distress syndrome …
A randomized trial of mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome from COVID-19
ME Bowdish, CE Barkauskas, JR Overbey… - American journal of …, 2023 - atsjournals.org
Rationale: There are limited therapeutic options for patients with coronavirus disease
(COVID-19)-related acute respiratory distress syndrome with inflammation-mediated lung …
(COVID-19)-related acute respiratory distress syndrome with inflammation-mediated lung …